Skip to Content

COVID-19 vaccine sales push Moderna past expectations in Q2

KIFI

By TOM MURPHY
AP Health Writer

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts. The company said Wednesday its Spikevax vaccine brought in $4.53 billion during the quarter. FactSet says analysts were looking for around $3.6 billion. Both numbers represent a drop from the nearly $6 billion in vaccine sales during the year’s first quarter, when a virus surge through the United States pushed more people to seek protection. But those sales could pick up again later this year. Moderna has developed an updated version of its vaccine for a fall booster campaign, and federal regulators recently endorsed the vaccine for children.

Article Topic Follows: AP National

Jump to comments ↓

Author Profile Photo

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content